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Trauma carries a large burden on health care resources. It is the lead-
ing cause of death among adults under the age of 50 years and repre-
sents a global mortality of 5 million people annually. Despite
preventivemeasures and advances in critical caremedicine, the number
of traumatic deaths is not decreasing [1,2]. Hemorrhage accounts for
30–40% of traumaticmortality and is only surpassed by neurologic inju-
ries as most common cause of death [3]. The physiological hemostatic
response to injury comprises a complex series of reactions, with activa-
tion of the coagulation cascade tominimize blood loss [4]. Through var-
ious anticoagulation and hyperﬁbrinolysis pathways however, this may
result in trauma-induced coagulopathy (TIC) [5,6]. TIC is diagnosed in
25–35% of trauma patients and is directly related to mortality [7].
Iatrogenic factors such as acidosis and hypothermiamay further impede
coagulation and together with TIC form a ‘lethal triad’ [8,9].
In order to manage these coagulation disorders, damage control re-
suscitation has been developed [10,11]. This strategy aims to achieve
rapid control of the source of bleeding, in combination with permissive
hypotension and hemostatic resuscitation. Permissive hypotension
guarantees an adequate systolic perfusion pressure while avoiding
dilutional coagulopathy [12]. Hemostatic resuscitation combines blood
product transfusion and administration of coagulation factor concen-
trates to correct trauma-induced coagulopathy. Recent literature
shows that the hemostatic effect of this strategy is most favourable
with transfusion of red blood cell concentrate, plasma and platelet ﬁl-
trate in a proportional ratio of 1:1:1 [13,14].
Coagulation management in hemostatic resuscitation can be guided
by conventional laboratory assays (CLA) or viscoelastic hemostaticstin time; CLA, conventional
mbin time; RBC, red blood cell
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time (PT) and activated partial thromboplastin time (APTT) have limita-
tions, since they only assess plasmatic coagulation and have prolonged
turnaround times. Consequently, they are insufﬁcient for correction of
trauma-induced coagulopathy [15,16]. Viscoelastic hemostatic assays
such as thromboelastometry (ROTEM) and thromboelastography
(TEG) can be used as point-of-care monitoring and provide insight in
the complete process of plasmatic and cellular clot formation, ﬁrmness
and dissolution. VHA-guided coagulation management has shown to
reduce bleeding, transfusion requirements and possibly mortality in
cardiothoracic and transplantation surgery [17]. The level of evidence
for its use in the traumatic population is however limited [18]. Trauma
guidelines currently recommend to combine CLA and VHA for coagula-
tion monitoring and resuscitation in these patients [19].
The aim of this studywas to evaluate the clinical effect of hemostatic
resuscitation in the traumatic population. We conducted a before-after
study that allowed us to compare the outcome in patients treated
with this strategy with a pre-intervention cohort. We hypothesized
that hemostatic resuscitation would result in a beneﬁcial clinical
outcome.2. Material and methods
2.1. Study design and setting
This observational study was conducted after implementation of a
hemostatic resuscitation protocol in January 2015 at the Erasmus
University Medical Center in Rotterdam, the largest level I trauma cen-
ter in The Netherlands. This protocol introduced the use of massive
transfusion packages with subsequent thromboelastometry-guided co-
agulationmanagement for patients with traumatic blood loss. The stan-
dardized massive transfusion packages consisted of three units of
270 mL red blood cell concentrate, three units of 200 mL plasma, one
combined unit of 350 mL platelet ﬁltrate from ﬁve donors, 2000 mg ﬁ-
brinogen concentrate and 2000 mg calcium gluconate. Furthermore,
all patients received a dose of tranexamic acid upon presentation
(1000 mg for patients b70 kg, 1500 mg for patients N70 kg).
Thromboelastometry analysis was performed by laboratory personnelthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Germany). Real-time thromboelastometry results were displayed
through the ROTEM Secure Viewer software (TEM International
GmbH, Munich, Germany). Physicians were trained in interpretation
of the thromboelastometry results and a ﬂowchart guided further coag-
ulation correction. This ﬂowchart was based on protocols from compa-
rable trauma centers and corresponds with recently published
treatment algorithms [20-23]. Supplemental administration of ﬁbrino-
gen concentrate, prothrombin complex concentrate, platelet ﬁltrate or
tranexamic acidwas given after interpretation of FIBTEM clot amplitude
at 10 min, EXTEM clotting time, EXTEM clot amplitude at 10 min and
EXTEM maximum lysis at 60 min respectively (Supplementary Fig. 1).
Activation of the protocol was carried out at discretion of the attending
trauma surgeon or anesthesiologist. This combined transfusion strategy
replaced a traditional protocol, where patients were primarily treated
with red blood cell concentrate (RBC) and crystalloids. In this traditional
strategy, administration of plasma, platelet ﬁltrate or coagulation factor
concentrates was only performed after extensive RBC transfusion.
Both protocols focused on prompt control of hemorrhage through
hemostatic interventions, in combination with permissive hypotension
and prevention of hypothermia, acidosis and hypocalcemia. After he-
modynamic stabilisation, RBC transfusionwas performed at a hemoglo-
bin level of 8.1 g/dL in both protocols (9.7 g/dL for patients
with underlying cardiovascular disease). For platelet transfusion, the
threshold was 75 × 109/L in hemostatic resuscitation and 60 × 109/L
in the traditional protocol. The hemostatic resuscitation protocol was
implemented simultaneously with the nationwide transition from sin-
gle donor fresh frozen plasma (310 mL Q-plasma, Sanquin, The
Netherlands) to pooled multi-donor solvent detergent plasma
(200 mL Omniplasma, Sanquin, The Netherlands).
The study was approved by the Medical Ethical Committee of the
ErasmusUniversity, Rotterdam, TheNetherlands. Theneed for informed
consent was waived due to the observational design of the study in
which patients were treated in adherence to routine institutional
guidelines.
2.2. Study population
Adult polytrauma patients were included in the study population if
they were primarily presented at the emergency department and re-
ceived ≥1750 mL of blood transfusions (equivalent to the volume of
onemassive transfusion package) within 24 h of admission. Polytrauma
was deﬁned as an Injury Severity Score (ISS) N15 resulting from injury
of at least two body regions. Patients admitted between January 2013
and December 2014 were compared to patients who presented be-
tween January 2015 and December 2016.
2.3. Data collection
All consecutive polytrauma patients were registered by the Trauma
Research Unit Department of the Erasmus University Medical Center.
Patients eligible for inclusion were anonymously registered in a study
database. The following variables were collected from their medical re-
cords: patient characteristics, vital parameters, mechanism of trauma,
Injury Severity Score, time between injury and presentation, Helicopter
Emergency Medical Services consultation, anticoagulant medication,
conventional laboratory assays, thromboelastometry results, blood
transfusion type and volume, coagulation concentrates, procoagulant
medication, mortality, length of stay on the intensive care, ventilation
days, renal replacement therapy, transfusion complications, thrombo-
embolic complications and length of stay in the hospital. Mechanism
of trauma was categorized as fall from height, trafﬁc accidents, gunﬁre
incidents, stabbing incidents or other injuries. Cause of death was cate-
gorized as exsanguination, neurologic and others. Laboratory results of
the assays performed shortest after emergency department presenta-
tion were documented in the database, with a maximum interval ofone hour after arrival. Calculated APACHE IV mortality was provided
by the national critical care registry. Mortality data were veriﬁed in
the national civil registration database.
2.4. Outcomes
The primary outcome was deﬁned as 30-day mortality. Secondary
outcomes were transfusion requirements in the ﬁrst 24 h of admission,
ICU length of stay in 30-day survivors and exsanguination as cause of
death.
2.5. Statistical analysis
Statistical analysis was performed using SPSS Statistics 25 (IBM,
Armonk, United States). Continuous data were checked for normal dis-
tribution by inspection of Q-Q plots and the Shapiro-Wilk test. Data
were presented as median with interquartile range (IQR) and frequen-
cies with percentages. Differences between populations were analyzed
using the Mann-Whitney U test for continuous variables and Fisher's
exact test for categorial variables. Effect on primary outcomes are pre-
sented by univariate odds ratios with 95% conﬁdence intervals. Thirty-
day survival was assessed with Kaplan-Meier analysis and log-rank
test. Statistical signiﬁcance was set at a p-value of b0.05 for all analyses.
3. Results
During 2013–2014, 822 polytrauma patients were presented at the
Erasmus University Medical Center compared to 845 patients in
2015–2016. After exclusion of pediatric patients, interhospital transfers
and patients not directly presented after injury, 611 and 595 patients
remained in both groups respectively. Evaluation of blood transfusion
requirement provided a study population of 57 patients in 2013–2014
and 65 patients in 2015–2016 who received transfusion of ≥1750 mL
blood products within 24 h.
The baseline characteristics (Table 1) show that patients had a me-
dian overall age of 48 years [IQR 32–60]. The 2013–2014 pre-
intervention population included a signiﬁcantly larger portion of male
patients (85% vs 65%, p b 0.001) and demonstrated a lower heart rate
at presentation (100 bpm [IQR 86–129] vs 117 bpm [IQR 100–130],
p= 0.046). Blood pressure, temperature and Glasgow Coma Scale did
not signiﬁcantly differ between groups. Trafﬁc accidents and fall from
height were the most common mechanisms of injury (45% and 29% re-
spectively). Traumatic brain injury was present in 67% of cases. Theme-
dian ISS was 34 [IQR 26–45] in both populations, with an overall
calculated APACHE IV mortality of 52% [IQR 7–77]. Eighty-one percent
of patients needed emergency surgery or embolization. Time to presen-
tation at the emergency departmentwas 48min [IQR 42–63] in the pre-
intervention group and 54 min [IQR 47–60] post-intervention (p =
0.85). Consultation of Helicopter Emergency Medical Services was not
different between groups (92% vs 86%, p= 0.20). Prehospital transfu-
sion of red blood cell concentrate, however, was signiﬁcantly more fre-
quently administered in the post-intervention population (0% vs 16%,
p b 0.001).
Laboratory results (Table 2) demonstrate that the hemoblogin level
at emergency department presentation did not signiﬁcantly differ be-
tween groups (10.6 g/dL [IQR 8.9–12.4] vs 11.3 g/dL [IQR 9.3–13.1],
p = 0.18). The median platelet count was lower in the pre-
intervention population (178 × 109/L [IQR 136–219] vs 203 × 109/L
[IQR 147–283], p = 0.025). Nevertheless, thrombocytopenia was not
signiﬁcantly more frequently observed (31% vs 25%, p = 0.52).
Thromboelastometry was performed in 2% of patients in the pre-
intervention population versus 49% post-intervention (p b 0.001).
Sixty-nine percent of these cases had abnormal thromboelastometry re-
sults, most frequently due to a limited FIBTEM clot amplitude (59%) or
prolonged EXTEM clotting time (52%). The Clauss ﬁbrinogen assay
was performed more frequently in the post-intervention population
Table 1
Baseline population characteristics at emergency department presentation.
Characteristics Pre-intervention
(n = 65)
Post-intervention
(n = 57)
p-Value
Age (years) 47 (33–60) 49 (32–59) 0.78
Male 55 (85%) 35 (61%) b 0.001
Heart rate (beats per minute)a 100 (86–129) 11 (100−130) 0.046
Tachycardia (≥100 beats per
minute)
35 (55%) 43 (80%) b 0.001
Systolic blood pressure
(mmHg)b
105 (80–128) 96 (80–138) 0.54
Hypotension (≤90 mmHg) 25 (42%) 22 (45%) 0.85
Temperature (Celsius)c 35.4 (34.0–36.0) 35.5 (34.5–36.2) 0.23
Hypothermia (≤35.0C) 20 (45%) 13 (32%) 0.27
Maximum Glasgow Coma Scale 8 (3–14) 7 (3–14) 0.72
Glasgow Coma Scale ≤8 35 (54%) 29 (51%) 0.86
Mechanism of trauma
Fall from height 19 (29%) 17 (30%) 1.00
Trafﬁc accident 28 (43%) 27 (47%) 0.72
Stabbing incident 6 (9%) 7 (12%) 0.77
Gunﬁre incident 3 (5%) 2 (4%) 1.00
Other 9 (14%) 4 (7%) 0.25
Blunt trauma 55 (85%) 48 (84%) 1.00
Traumatic brain injury 42 (65%) 40 (70%) 0.57
Injury Severity Score 34 (25–44) 34 (27–48) 0.48
APACHE IV mortality (%) 49 (6–76) 63 (11–80) 0.64
Helicopter Emergency Medical
Services
60 (92%) 49 (86%) 0.20
Time to presentation (minutes) 48 (42–63) 54 (47–60) 0.85
Prehospital intubation 44 (68%) 37 (65%) 0.45
Prehospital transfusion 0 9 (16%) b 0.001
Transfusion on emergency
department
49 (75%) 43 (75%) 0.84
Emergency surgery or
embolization
52 (80%) 47 (82%) 0.82
Anticoagulant medication
Antiplatelet therapy 3 (5%) 1 (2%) 0.62
Vitamin K antagonists 0 3 (5%) 0.10
Categorial variables presented as numbers (%) with p-values from Fisher's exact test; con-
tinuous variables presented as median (interquartile range) with p-values from Mann-
Whitney U test.
a Excluding patients with missing variables; pre-intervention: 1 patient (2%), post-in-
tervention: 3 patients (5%).
b Excluding patients that were lost to follow-up; pre-intervention: 5 patients (8%),
post-intervention: 8 patients (14%).
c Excluding patients that were lost to follow-up; pre-intervention: 21 patients (32%),
post-intervention: 16 patients (28%).
Table 2
Laboratory analysis results.
Laboratory results Pre-intervention
(n = 65)
Post-intervention
(n = 57)
p-Value
Hemoglobin (g/dL) 10.6 (8.9–12.4) 11.3 (9.5–13.1) 0.18
Analyzed patients 61 (94%) 54 (95%) 1.00
Anemia (b9 g/dL) 16 (26%) 8 (15%) 0.17
pH 7.16 (7.09–7.26) 7.21 (7.01–7.28) 0.65
Analyzed patients 49 (75%) 48 (84%) 0.27
Acidosis (b7.30) 42 (86%) 38 (79%) 0.44
Lactate (mmol/L) 4.5 (2.9–7.1) 4.0 (3.0–8.3) 0.71
Analyzed patients 47 (72%) 44 (77%) 0.68
Hyperlactatemia (N2 mmol/L) 39 (83%) 39 (89%) 0.55
Base deﬁcit (mEq/L) 10 (7–13) 9 (6–15) 0.99
Analyzed patients 47 (72%) 47 (82%) 0.20
Elevated (N4 mEq/L) 41 (87%) 38 (81%) 0.57
Platelet count (109/L) 178 (136–219) 203 (147–283) 0.025
Analyzed patients 54 (83%) 52 (91%) 0.28
Thrombocytopenia
(b150 × 109/L)
17 (31%) 13 (25%) 0.52
INRa 1.4 (1.3–1.6) 1.3 (1.1–1.6) 0.08
Analyzed patients 46 (71%) 47 (82%) 0.14
Prolonged (N1.5) 12 (26%) 14 (30%) 0.82
APTT (seconds) 30 (25–45) 35 (24–50) 0.68
Analyzed patients 41 (63%) 40 (72%) 0.45
Prolonged (N60 s) 5 (12%) 9 (23%) 0.25
Fibrinogen (g/L) 1.0 (0.6–2.2) 1.6 (1.2–1.8) 0.34
Analyzed patients 3 (5%) 34 (60%) b 0.001
Hypoﬁbrinogenemia (b1.5 g/L) 2 (67%) 14 (41%) 0.57
Thromboelastometry
Analyzed patients 1 (2%) 28 (49%) b 0.001
Abnormal EXTEM / FIBTEM 1 (100%) 19 (68%) 1.00
Categorial variables presented as numbers (%) with p-values from Fisher's exact test; con-
tinuous variables presented as median (interquartile range) with p-values from Mann-
Whitney U test.
a Excluding patients using vitamin K antagonists; pre-intervention: no patients, post-
intervention: 3 patients (5%).
Table 3
Blood transfusion and coagulation treatment within the ﬁrst 24 h.
Therapy Pre-intervention
(n = 65)
Post-intervention
(n = 57)
p-Value
Red blood cell concentrate
Treated patients 65 (100%) 57 (100%) 1.00
Dose (mL) 2160
(1350–4995)
2160
(1350–3240)
0.67
Plasma
Treated patients 63 (97%) 57 (100%) 0.50
Dose (mL) 2170
(1240–5580)
1400 (700–2100) b 0.001
Platelet ﬁltrate
Treated patients 42 (65%) 55 (96%) b 0.001
Dose (mL) 700 (350–1400) 350 (350–1050) 0.27
Fibrinogen concentrate
Treated patients 13 (20%) 42 (74%) b 0.001
Dose (mg) 4000
(2500–6000)
2000
(2000–4000)
0.16
Tranexamic acid
Treated patients 51 (78%) 47 (82%) 0.65
Dose (mg) 2000
(1000−3000)
2000
(1000–3000)
0.87
Calcium gluconate
Treated patients 54 (83%) 52 (91%) 0.28
Dose (mg) 2000
(1000–4000)
3000
(2000–6000)
0.034
Prothrombin complex
concentrate
Treated patients 7 (11%) 12 (21%) 0.14
Dose (IU) 2000 (750–2500) 1125 (625–2000) 0.54
Categorial variables presented as numbers (%) with p-values from Fisher's exact test; con-
tinuous variables presented as median (interquartile range) with p-values from Mann-
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not signiﬁcantly different between groups (1.0 g/L [IQR 0.6–2.2] vs
1.6 g/L [IQR 1.2–1.8], p= 0.34). Other conventional laboratory results
did neither reveal signiﬁcant difference. The prevalence of any type of
coagulation disorder at the moment of presentation was 40% in the
pre-intervention population versus 56% post-intervention (p= 0.12).
Adherence to the hemostatic resuscitation protocol in 2015–2016
was 65%. Table 3 provides the results for blood transfusion and coagula-
tion management in the ﬁrst 24 h of admission. Patients received red
blood cell concentrate transfusion in a median dose of 2160 mL [IQR
1350–3645] in both groups. The volume of plasma transfusion was sig-
niﬁcantly lower in the post-intervention population (2170 mL [IQR
1240–5580] vs 1400 mL [IQR 700–2100], p b 0.001). Meanwhile, the
post-intervention populationwasmore frequently treatedwith platelet
ﬁltrate (65% vs 96%, p b 0.001) and ﬁbrinogen concentrate (20% vs 74%,
p b 0.001). The median volume of platelet ﬁltrate administration was
700 mL [IQR 350–1400] in the pre-intervention cohort compared to
350 mL [IQR 350–1050] post-intervention (p = 0.27). For patients
that received ﬁbrinogen concentrate, median doses were 4000 mg
[IQR 2500–6000] and 2000 mg [IQR 2000–4000] respectively (p =
0.16). Furthermore, themedian administered dose of calcium gluconate
was higher in the post-intervention population (2000 mg [IQR
1000–4000] vs 3000 mg [IQR 2000–6000], p = 0.034). Treatmentwith tranexamic acid and prothrombin complex concentrate did notWhitney U test.
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All cause 30-day mortality was 43% in the pre-intervention popula-
tion versus 51% post-intervention (p = 0.47; Table 4). Kaplan-Meier
analysis did not show signiﬁcant difference in 30-day survival (Fig. 1,
log-rank p= 0.41). Causes of death were similarly distributed in both
study populations, with exsanguination representing 32% of cases pre-
intervention versus 24% post-intervention (p = 0.57). After excluding
patients with a neurologic cause of death, 30-day mortality did not
change (23% vs 26%, p= 0.80, log-rank p= 0.74). Secondary outcome
ICU length of stay in 30-day survivors was not signiﬁcantly different be-
tween groups (6.0 vs 8.0 days, p= 0.30), nor was the amount of venti-
lation days (3.0 vs and 5.5 days, p = 0.53) or hospital length of stay
(31.0 vs 27.0 days; p=0.25). Post-hoc analysis only comparing patients
that were treated in adherence to the hemostatic resuscitation protocol
did not change primary or secondary outcomes (Supplementary Table 1
and Supplementary Fig. 2). Renal replacement therapy, thromboem-
bolic complications and transfusion reactions were infrequently re-
ported and did not show signiﬁcant difference in distribution between
groups.
4. Discussion
This study was performed to evaluate the effect of a hemostatic re-
suscitation strategy that combines the use of massive transfusion pack-
ages and thromboelastometry-guided coagulation management in
patients with trauma-induced coagulopathy. Our ﬁndings demonstrate
that in a population with 65% protocol adherence, application of hemo-
static resuscitation increases the frequency of platelet ﬁltrate and ﬁbrin-
ogen concentrate administration, while reducing the volume of plasma
transfusion. The outcome results observed in our population do not in-
dicate a favourable trend with regards to mortality, exsanguination or
ICU length of stay.
Our study underlines the difﬁculty of adequate hemostatic manage-
ment in the traumatic population. The multifactorial causes of bleeding
together with problematic source control and trauma-induced coagu-
lopathy make traumatic hemorrhage incomparable to other types of
bleeding. Results from studies performed in patients with hemorrhage
due to other conditions do therefore not necessarily translate to the
traumatic population. The beneﬁcial effect of hemostatic resuscitation
described in cardiothoracic surgery was not reproduced in our trial
[17]. A previous study by Johannson et al. demonstrated a decrease in
30-day mortality after implementation of a hemostatic resuscitationTable 4
Primary and secondary outcome variables comparing patients treated before versus after impl
Outcome Pre-intervention (n = 65)
Mortality
24 h 20 (31%)
7 days 25 (39%)
30 days 28 (43%)
Cause of death
Neurologic injury 17 (61%)
Exsanguination 9 (32%)
Other 2 (7%)
Mortality neurology excluded
24 h 9 (19%)
7 days 11 (23%)
30 days 11 (23%)
ICU length of stay in 30-day survivors (days)a,b 6.0 (2.0–15.8)
Ventilation support in 30-day survivors (days)a,b 3.0 (1.3–12.8)
Hospital length of stay in 30-day survivors (days)a,c 31.0 (22.5–56.8)
Renal replacement therapyb 2 (3%)
Thromboembolic complicationsc 2 (3%)
Transfusion reactions 0
Categorial variables presented as numbers (%)with p-values from Fisher's exact test; continuou
test.
a Excluding patients that died at the emergency department or operating theatre prior to cli
b Excluding patients that were lost to follow-up; 1 patient in 2013–2014, no patients in 201
c Excluding patients that were lost to follow-up; 5 patients in 2013–2014, 1 patient in 2015protocol similar to the one used in this study [24]. Their population,
however, included a relatively large fraction of vascular and cardiotho-
racic surgery patients, with trauma representing only 14.5% of cases.
Our results exclusively in patients with traumatic hemorrhage do not
indicate a similar trend. A multicenter randomized controlled trial is
currently being undertaken to further clarify the potential clinical effect
of thromboelastometry-guided hemostatic resuscitation in trauma pa-
tients [23].
Approximately half of the patients in our study population suffered
from coagulation disorders upon presentation at the emergency depart-
ment. This corresponds to the prevalence of trauma-induced coagulop-
athy previously reported [25,26]. These ﬁndings emphasize the
importance of expeditious coagulation analysis in trauma patients. As
stated in trauma guidelines, point-of-care thromboelastometry moni-
toring may shorten turnaround times and thereby improve insight
in patient coagulation status compared to conventional laboratory
assays [19].
Considering the pathophysiological effects of trauma-induced coag-
ulopathy, we anticipated an increase in platelet ﬁltrate transfusion as
observed in our post-intervention population. Nevertheless, this does
not correspond to the results of a recent trial by Gonzalez et al. [27].
Their study evaluated the effect of a massive transfusion protocol
where suppletion of coagulation factor concentrates was either directed
by conventional laboratory assays or thromboelastography. Patients
treated with the thromboelastography-guided protocol demonstrated
a signiﬁcant reduction in both plasma and platelet ﬁltrate transfusion
and had improved 28-day survival.
The reduction in plasma transfusion volume observed after imple-
mentation of the hemostatic resuscitation protocol may be the result
of adequate coagulation factor concentrate utilization. However, the si-
multaneous nationwide transition from single-donor fresh frozen
plasma in a volume of 310mL per unit tomulti-donor solvent detergent
plasma in a volume of 200 mL per unit presumably affected these ﬁnd-
ings. The frequency of treatment with plasma, platelet ﬁltrate and coag-
ulation factor concentrates observed in the pre-intervention population
indicates a more liberal administration of these products than
instructed in the protocol applicable at that time. Most likely, evidence
from studies on hemostatic resuscitation prior to implementation of
our protocol stimulated physicians to already adopt parts of this strat-
egy in their clinical practice. This may have led to a potential underesti-
mation of the effect of hemostatic resuscitation in our patients.
Furthermore, the time of blood product administration wasementation of hemostatic resuscitation.
Post-intervention (n = 57) p-Value Odds ratio (95% CI)
17 (30%) 1.00 0.96 (0.44–2.07)
26 (46%) 0.47 1.34 (0.65–2.77)
29 (51%) 0.47 1.37 (0.67–2.80)
19 (66%) 0.79 1.23 (0.42–3.61)
7 (24%) 0.57 0.67 (0.21–2.15)
3 (10%) 1.00 1.50 (0.23–9.73)
7 (18%) 1.00 0.92 (0.31–2.74)
10 (26%) 0.80 1.20 (0.45–3.22)
10 (26%) 0.80 1.20 (0.45–3.22)
8.0 (3.0–14.5) 0.30
5.5 (2.0–9.8) 0.53
27.0 (16.0–51.0) 0.25
1 (2%) 1.00
3 (5%) 1.00
1 (2%) 0.48
s variables presented asmedian (interquartile range)with p-values fromMann-WhitneyU
nical admission; 6 patients in 2013–2014, 5 patients in 2015–2016.
5–2016.
–2016.
Fig. 1. Cumulative survival rate for patients treated before (2013–2014) versus after (2015–2016) implementation of hemostatic resuscitation.
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of plasma may have delayed the logistic distribution of this product,
thereby affecting the sequence of blood product transfusion. The vol-
ume of crystalloid and colloid administration could neither reliably be
collected from the medical records of our patients. A possible transition
in treatment with these products could therefore not be assessed. Due
to these limitations, the deﬁnite effect of plasma transfusion in trauma
patients cannot be addressed with this study. Results from previous tri-
als, however, indicate that due to processing and storage, the effective-
ness of plasma transfusion on reversal of coagulation disorders is
probably limited [28]. Innerhofer et al. recently reported a reduction
of blood transfusion requirement and morbidity in trauma patients
treated with ﬁbrinogen concentrate, prothrombin complex concentrate
and factor XIII, compared to treatment with plasma [29]. Taking all
results into account, we believe that the use of coagulation factor con-
centrates should be stimulated in patients with trauma-induced
coagulopathy.
Adherence to treatment protocols in the emergency department is
highly variable, mostly due to time constraints and the clinical setting
of unscheduled patient care [30]. In order to optimize compliance, we
developed an extensive implementation program, which included con-
gress meetings, poster reminders and educational visits with audit and
feedback at all involved departments. The adherence rate observed in
our study population is consistent with previously described results in
trauma patients [31]. There seems to be a correlation between guideline
compliance and in-hospital mortality in the traumatic population [32].
Future studies should therefore focus on optimization of strategies for
emergency department protocol implementation, in order to further
improve the quality of trauma care.
Amajor limitation to our study is the population size, due to our sin-
gle center design. Despite thorough selection of our study population,
exsanguination only represented cause of death in a limited group of
patients. The infrequency of this clinical endpoint affects the reliability
of our ﬁndings and therefore the effect of hemostatic resuscitation on
exsanguination cannot be determined with this study. Post-hoc power
calculations are not recommended by literature [33]. We emphasize
that a statistical type II error is not excluded and might impede our
study results.
Another limitation is a potential chronological bias due to the
before-after design of our study. Thiswould howevermost likely beneﬁt
the post-intervention population, for example reﬂected by the increasein prehospital blood transfusions. Since the results of hemostatic resus-
citation in our post-intervention population lack an outcome beneﬁt, it
is relatively unlikely that undocumented confounding factors signiﬁ-
cantly constrain this conclusion. A multicenter study with consecutive
protocol implementation at each site would be necessary in order ad-
dress both these restrictions.5. Conclusion
This study emphasizes the problematic management of hemorrhage
in trauma patients and demonstrates the difﬁculty of implementing a
protocolized resuscitation strategy. Our results do not indicate that the
use of a hemostatic resuscitation protocol with massive transfusion
packages and thromboelastometry-guided coagulation management
causes a favourable trend in 30-day mortality or intensive care length
of stay. Due to the limitations of our study, the optimal resuscitation
strategy in traumatic hemorrhage will have to be determined by future
research.
Supplementary data to this article can be found online at https://doi.
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